Neoleukin Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch NLTX and buy or sell other stocks, ETFs, and their options commission-free!About NLTX
Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in May 2007 and is headquartered in New York, NY.
CEORachel L. McMinn, PhD
CEORachel L. McMinn, PhD
Employees107
Employees107
HeadquartersNew York, New York
HeadquartersNew York, New York
Founded2018
Founded2018
Employees107
Employees107
NLTX Key Statistics
Market cap429.36M
Market cap429.36M
Price-Earnings ratio-5.78
Price-Earnings ratio-5.78
Dividend yield—
Dividend yield—
Average volume323.32K
Average volume323.32K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$74.49
52 Week high$74.49
52 Week low$6.88
52 Week low$6.88
Stock Snapshot
Neoleukin Therapeutics(NLTX) stock is priced at $30.09, giving the company a market capitalization of 429.36M. It carries a P/E multiple of -5.78.
During the trading day, Neoleukin Therapeutics(NLTX) stock saw an opening price of —, a peak of —, and a bottom of —.
Trading volume for Neoleukin Therapeutics(NLTX) stock has reached 0, versus its average volume of 323.32K.
The stock's 52-week range extends from a low of $6.88 to a high of $74.49.
The stock's 52-week range extends from a low of $6.88 to a high of $74.49.
People also own
Based on the portfolios of people who own NLTX. This list is generated using Robinhood data, and it’s not a recommendation.